Skip to main content
OpenTrials
Completed

NCT Number: NCT02127515

Non Invasive Prenatal Testing of Down Syndrome

This is a randomized controlled trial in women at risk following combined prenatal screening for Down Syndrome. Women will be asked about their preferences between NIPT and routine prenatal diagnosis based on a dedicated questionnaire. Women will then be randomized between NIPT and standard invasive prenatal diagnosis.

Completed

Looking for future studies?

Notify Me

Key information

About this study

This is a randomized controlled trial in women at risk following combined prenatal screening for Down Syndrome. Women will be asked about their preferences between NIPT and routine prenatal diagnosis based on a dedicated questionnaire. Women will then be randomized between NIPT and standard invasive prenatal diagnosis.

The general objectives are :

  • Promote the rapid and large implementation of Non Invasive Prenatal Testing (NIPT) for Down syndrome.
  • Improve the management of women at risk after combined first trimester screening and reduce the number of invasive procedures and induced miscarriages .
  • Evaluate NIPT medically (in reducing the rate of invasive sampling and related complications, diagnostic performance and feasibility and acceptability in routine practice) and based on cost-analysis in comparison with standard invasive prenatal diagnosis currently proposed .
  • Clarify the conditions of implementation and dissemination of NIPT in the overall organization of prenatal screening for trisomy 21 (and provide data to later adjust or not the combination of tests and thresholds).

Promote the organization as networks of professionals involved in prenatal screening for trisomy 21 in order to allow the emergence of a national system of collection of outcomes to improve the quality of practices

The main judgement criteria are:

  • Main:
  • Percentage of fetal loss in each group
  • Secondary:
  • Percentage of invasive tests in each group (amniocentesis or chorionic villus sampling )
  • Diagnostic performance of NIPT , in particular false positive and negative
  • Percentage of results within 3 weeks and average time interval for results of NIPT
  • Percentage of inconclusive results of DPANI
  • Percentage of other anomalies discovered at invasive sampling
  • Percentage of invasive samples taken despite normal NIPT (either because of later ultrasound anomaly or for maternal reinsurance)
  • Association between maternal characteristics ( weight, height, parity , previous history , serum markers ... ) and the results of NIPT
  • Cost analysis of NIPT in routine clinical practice

The study will include 2450 high risk women in order to be powered enough to detect a 1% reduction of miscarriages in the group undergoing NIPT instead of routine invasive prenatal diagnosis.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • pregnant women over 18
  • at risk for Down syndrome> 1/250 based on combined screening using ultrasound together with maternal serum markers and prior to fetal karyotyping
  • singleton pregnancy
  • pregnancy between 11SA et 18SA
  • willing a fetal karyotype

Exclusion criteria

  • risk for Down syndrome< 1/250 or >1/5
  • NT> 3 mm, PAPP-A or beta HCG <0.3 MoM or >5 MoM
  • multiple pregnancy , vanishing twin
  • morphological abnormalities at US
  • Kown chromosomal anomaly in parents
  • Patients not willing a fetal karyotype

Treatment and study plan

Non Invasive Prenatal Testing

Procedure

Invasive Prenatal Testing

Procedure

Primary outcomes

  1. Number or miscarriages

    Time frame: at birth

Secondary outcomes

  1. Number or invasive tests

    Time frame: at birth

  2. false positive and negative rates of NIPT

    Time frame: At birth

  3. Dedicated questionnaire for patients

    Time frame: day 5

  4. Cost of invasive tests and NIPT in euros

    Time frame: at birth

    measure in euros

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Collaborators

  • URC-CIC Paris Descartes Necker Cochin

Registry information

Official study title

Non Invasive Prenatal Testing of Down Syndrome From Maternal Blood Sample

Acronym: SAFE 21

Important dates

Study start
2014
Primary completion
2016
Study completion
2016
First posted
Apr 30, 2014
Registry last updated
Sep 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.